Part of the
Stem Cell Revolution

Stem cells are expected to revolutionize the treatment of today's severe and incurable diseases. NextCell develops pioneering stem cell therapies for the treatment of autoimmune and inflammatory diseases as well as for use in organ transplants.

Technology

NextCell develops ProTrans™, a drug candidate consisting of stem cells for the treatment of autoimmune diseases, initially focusing on type- 1 diabetes. ProTrans is based on NextCell patent pending Selection Algorithm. Further, NextCell runs Cellaviva, Nordic's largest private stem cell bank, approved by IVO.
Read more

ProTrans shows significant effect in Diabetes

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).

Read more

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from umbilical cord. NextCell is focusing on research and development of novel stem cell therapies and is also running a tissue establishment and primary biobank, classified as healthcare provider.
Sample in a lab is being examinedRead more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Cover art of NextCell report
Read our latest report:
Interim Report 1 2022/2023
Download

News

2023-01-26

NextCell publishes its Interim Report 1 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Ma
Read moreRead more
2023-01-25

ProTrans study in COVID-19 expanded to include treatment of severe pneumonia induced by influenza A, RSV and HMP virus

NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has approved the expansion of their Swedish COVID-19 study, to include patients with severe pneumonia due to influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (HMP). The treatment is aimed
Read moreRead more
2023-01-18

Positive feedback on the paediatric plan of the EMA

NextCell Pharma AB ("NextCell") has received positive comments and recommendations for the pediatric investigational plan (PIP) submitted to the Europeans Medicines Agency’s (EMA) pediatric committee (PDCO).
Read moreRead more
2022-12-21

First pediatric patients treated with ProTrans in type-1 diabetes phase II study

NextCell Pharma AB ("NextCell") supports the pediatric diabetes clinical trial conducted at Uppsala University Hospital by Principal Investigator Professor Per-Ola Carlsson with the stromal cell treatment, ProTrans. At the end of October 2022, the Data Safety and Monitoring Board recommended that ph
Read moreRead more
All news